Roche Palo Alto LLC

Principia Biopharma Inc.

Syntex (u.s.a.) Inc.

Other

Poche Palo Alto LLC

University of California

F. Hoffmann-la Roche Ag

David Michael Goldstein

James Patrick Dunn

Eric Brian Sjogren

Kenneth Albert Brameld

Jian Jeffrey Chen

Timothy D Owens

David Mark Rotstein

Yan Lou

Leyi Gong

Christoph Martin Stahl

Ronald Charles Hawley

Francisco Xavier Talamas

Sharada Shenvi Labadie

Nolan James Dewdney

Wylie Solang Palmer

Humberto Bartolome Arzeno

Tobias Gabriel

Joan Heather Hogg

Soan Cheng

Roland Joseph Billedeau

Tania M Silva

Counde O'Yang

Achyutharao Sidduri

Michael Soth

Christophe Michoud

Erik J Verner

Bret Berner

Frederick Arthur Brookfield

Michael Patrick Dillon

Bernd Buettelmann

Alam Jahangir

Lawrence Emerson Fisher

Matthias Rueth

Xiaochun Han

Julie Anne Lim

Teresa Alejandra Trejo-Martin

Alfred Sui-Ting Lui

Nidhi Arora

Teresa Alejandra Trejo Martin

Deborah Carol Reuter

Parcharee Tivitmahaisoon

Teresa Rosanne Welch

Ian Edward David Smith

William Harris

Shao-Yong Wu

Bradley E Loe

Pravin Iyer

Kristen Lynn McCaleb

Tim Owens

Lubica Raptova

Jaehyeon Park

John William Taunton

Shyam Krishnan

Yun-chou Tan

Sarah C Abbot

Geneviève N Boice

Lubov Konstantinovna Filonova

Jesse McFarland

Florence Eustache

Christopher Huw Hill

Jonathan Choy

Levi Gong

Erin M O'Brien

Yun-Chou Tan

Jesse Mcfarland

Timothy Duncan Owens

Lubov Filonova

Tania Silva

Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Immunoproteasome inhibitors

Provided herein are compounds, such as a compound of Formula (I), or a pharmaceutically acceptable salt thereof that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present disclosure provides compounds of formula (I) that are tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ('BTK') inhibitors, and are therefore useful for the treatment of diseases treatable by inhibition of BTK such as cancer, autoimmune, inflammatory, and thromboembolic diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds. 

Heterocycle comprising tyrosine kinase inhibitors

Provided herein are compounds, such as a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof, that are immunoproteasome (such as LMP2 and LMP7) inhibitors. The compounds described herein can be useful for the treatment of diseases treatable by inhibition of immunoproteasomes. Also provided herein are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

The present invention relates to an improved water pipe comprising a chamber containing water in its lower portion, its upper compact cylindrical portion serving as a smoke collection reservoir; a bowl for combusting tobacco or medicinal herbs, the smoke directed through a tube to the water chamber below the water; and a mouth piece for applying suction to the interior of the chamber to inhale the smoke.

System, apparatus and methods for a particulate filtration

The present invention relates to a glass laboratory apparatus that eliminates a pre filter and a provides a simpler vaporizing platform in fluid communication with a fitted disc filter arranged in an exhaust chamber to scrub solids from a gas using water filtration. A preferred embodiment of the present invention includes a main vessel adapted to hold a volume of a liquid such as water and an inlet conduit with an opening above the liquid level in the main vessel. The inlet conduit includes a vaporizing platform with a platform having four ventilated regions surrounding the platform.

Laboratory apparatus

The present disclosure provides compounds of formula (I) wherein the variables are as defined herein that are JAK3 inhibitors and therefore useful for the treatment of diseases treatable by inhibition of JAK3 such as cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Substituted pyrrolo[2,3-b]pyrazines as JAK3 inhibitors

The present disclosure provides compounds of Formula (I)and pharmaceutically acceptable salts that are tyrosine kinase inhibitors,in particular BLK, BMX, EGFR, HER2, HER4, ITK, Jak3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts. 

Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors

The present disclosure provides compounds and pharmaceutically acceptable salts that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, JAK3, TEC, Btk, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts and processes for preparing such compounds and pharmaceutically acceptable salts.

Azaindole derivatives as tyrosine kinase inhibitors

The present disclosure provides compounds and pharmaceutically acceptable salts thereof that are tyrosine kinase inhibitors, in particular BLK, BMX, EGFR, HER2, HER4, ITK, TEC, BTK, and TXK and are therefore useful for the treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like. Also provided are pharmaceutical compositions containing such compounds and pharmaceutically acceptable salts thereof and processes for preparing such compounds and pharmaceutically acceptable salts thereof.

Tyrosine kinase inhibitors

The present invention relates to a glass laboratory apparatus that includes a pre filter and a main filter to scrub solids from a gas using water filtration. A preferred embodiment of the present invention includes a main vessel adapted to hold a volume of a liquid such as water and an inlet conduit with an opening above the liquid level in the main vessel and an outlet below the surface of the liquid level in the main vessel. A pre filter arranges in the inlet conduit at a level above the liquid level in the main vessel. A main filter is located below the water level in the main vessel. A negative pressure is supplied to draw a gas through the first, pre-filter, through the water and second main filter.

Compounds of formula I modulate jnk and cdk: or a pharmaceutically acceptable salt thereof, where R, R, R, R, and m are defined herein.

Benzotriazole kinase modulators

Growing community of inventors

San Jose, CA, United States of America

David Michael Goldstein